What's in Melinta Therapeutics's pipeline?

Melinta Therapeutics has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Melinta Therapeutics's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/melinta.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Melinta Therapeutics — Portfolio Competitive Intelligence Brief

Melinta Therapeutics (MLNT) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

MLNT (NASDAQ) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Baxdela	DELAFLOXACIN	marketed	Fluoroquinolone Antibacterial		Infectious Disease	2017-01-01

Therapeutic area mix

Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Melinta Therapeutics:

Cite this brief

Drug Landscape (2026). Melinta Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/melinta. Accessed 2026-05-14.